Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again

Core Viewpoint - The article emphasizes a strong buy case for Novo Nordisk (NVO), suggesting that recent stock pullbacks are merely noise and do not reflect the company's underlying value [1]. Group 1: Investment Thesis - The author has maintained a Strong Buy rating on Novo Nordisk since July 1, indicating confidence in the stock's potential for growth despite market fluctuations [1]. - The investment strategy focuses on identifying undervalued stocks across various industries using quantitative methods that have been backtested for success [1]. Group 2: Author's Background - The author has been investing since 2013 and has gained knowledge from extensive reading on stock market strategies, including notable books such as "100 Baggers," "Financial Shenanigans," and "The Quants" [1].